Compare Stocks: ELOX, SIGA, NERV, and DERM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$7.86 -0.5%	$6.95	$4.31 ▼ $9.56	$221.81M	1.09	219,503 shs	51,229 shs
ELOX Eloxx Pharmaceuticals	$15.00 +5.7%	$15.00	$8.20 ▼ $23.40	$60.54M	-1862.26	55,091 shs	38,841 shs
NERV Minerva Neurosciences	$4.43 -5.5%	$4.54	$1.93 ▼ $12.46	$211.53M	-0.08	215,417 shs	78,435 shs
SIGA Siga Technologies	$3.29 +1.9%	$3.29	$2.83 ▼ $9.45	$236.39M	0.97	612,860 shs	899,421 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	+1.67%	+4.91%	+22.61%	+32.33%	+13.67%
ELOX Eloxx Pharmaceuticals	-10.42%	-11.31%	-23.01%	-68.30%	+117,172.73%
NERV Minerva Neurosciences	+4.69%	-8.58%	+16.09%	-5.44%	+95.42%
SIGA Siga Technologies	+0.62%	+5.56%	-0.31%	-24.88%	-62.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$7.86 -0.5%	$6.95	$4.31 ▼ $9.56	$221.81M	1.09	219,503 shs	51,229 shs
ELOX Eloxx Pharmaceuticals	$15.00 +5.7%	$15.00	$8.20 ▼ $23.40	$60.54M	-1862.26	55,091 shs	38,841 shs
NERV Minerva Neurosciences	$4.43 -5.5%	$4.54	$1.93 ▼ $12.46	$211.53M	-0.08	215,417 shs	78,435 shs
SIGA Siga Technologies	$3.29 +1.9%	$3.29	$2.83 ▼ $9.45	$236.39M	0.97	612,860 shs	899,421 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	+1.67%	+4.91%	+22.61%	+32.33%	+13.67%
ELOX Eloxx Pharmaceuticals	-10.42%	-11.31%	-23.01%	-68.30%	+117,172.73%
NERV Minerva Neurosciences	+4.69%	-8.58%	+16.09%	-5.44%	+95.42%
SIGA Siga Technologies	+0.62%	+5.56%	-0.31%	-24.88%	-62.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DERM Journey Medical	2.25	Hold	$14.00	78.12% Upside
ELOX Eloxx Pharmaceuticals	2.75	Moderate Buy	$41.50	176.67% Upside
NERV Minerva Neurosciences	1.75	Reduce	$10.33	133.26% Upside
SIGA Siga Technologies	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ELOX, SIGA, NERV, and DERM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$43.00
8/20/2026	ELOX Eloxx Pharmaceuticals	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	ELOX Eloxx Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/13/2026	DERM Journey Medical	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00 ➝ $15.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/11/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
7/22/2026	ELOX Eloxx Pharmaceuticals	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$40.00
7/20/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$43.00
7/20/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$43.00
7/17/2026	DERM Journey Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DERM Journey Medical	$61.86M	3.59	N/A	N/A	$1.14 per share	6.89
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	$11.50 per share	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($4.47) per share	N/A
SIGA Siga Technologies	$94.57M	2.50	$0.34 per share	9.64	$2.30 per share	1.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DERM Journey Medical	-$11.43M	-$0.22	N/A	8.73	N/A	-8.95%	-20.23%	-6.60%	11/11/2026 (Estimated)
ELOX Eloxx Pharmaceuticals	-$5.99M	-$1.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)
SIGA Siga Technologies	$23.28M	-$0.05	N/A	N/A	N/A	-5.19%	-1.55%	-1.32%	11/5/2026 (Estimated)

Latest ELOX, SIGA, NERV, and DERM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	DERM Journey Medical	-$0.0225	-$0.01	+$0.0125	-$0.01	$18.36 million	$18.51 million
8/11/2026	Q2 2026	ELOX Eloxx Pharmaceuticals	N/A	-$0.66	N/A	-$0.66	N/A	N/A
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A
8/6/2026	Q2 2026	SIGA Siga Technologies	N/A	$0.17	N/A	$0.17	N/A	$41.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DERM Journey Medical	0.64	1.59	1.41
ELOX Eloxx Pharmaceuticals	N/A	3.74	3.74
NERV Minerva Neurosciences	N/A	20.15	20.14
SIGA Siga Technologies	N/A	21.72	16.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DERM Journey Medical	7.25%
ELOX Eloxx Pharmaceuticals	2.90%
NERV Minerva Neurosciences	34.56%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
DERM Journey Medical	14.53%
ELOX Eloxx Pharmaceuticals	25.90%
NERV Minerva Neurosciences	1.70%
SIGA Siga Technologies	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DERM Journey Medical	90	28.22 million	24.12 million	N/A
ELOX Eloxx Pharmaceuticals	N/A	4.04 million	2.99 million	N/A
NERV Minerva Neurosciences	9	47.75 million	46.94 million	Not Optionable
SIGA Siga Technologies	40	71.85 million	69.89 million	Optionable

ELOX, SIGA, NERV, and DERM Headlines

Recent News About These Companies

BlackRock Inc. Makes New $15.24 Million Investment in Siga Technologies Inc. $SIGA

September 4 at 3:28 AM | marketbeat.com

Siga Technologies (NASDAQ:SIGA) Shares Up 2.6% - Should You Buy?

August 31, 2026 | marketbeat.com

NASDAQ Composite Index-Wert SIGA Technologies-Aktie: So viel hätten Anleger mit einem Investment in SIGA Technologies von vor 10 Jahren verdient

August 31, 2026 | finanzen.netF

SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Siga Technologies Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

SIGA Technologies 2026年第二季度每股收益$0.17，盘后股价小幅上涨

August 6, 2026 | cn.investing.com

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026

August 6, 2026 | markets.businessinsider.com

SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results

July 30, 2026 | globenewswire.com

Siga Technologies: Q2 Earnings Due, New TPOXX Orders A Must

July 28, 2026 | seekingalpha.com

Is SIGA Technologies’ (SIGA) Index Shift and ESOP Shelf Registration Reframing Its Defensive Identity?

June 30, 2026 | finance.yahoo.com

Discovering SIGA Technologies And 2 Other Compelling Penny Stocks

May 22, 2026 | finance.yahoo.com

SIGA Technologies (SIGA) Is Down 9.9% After Q1 Revenue Miss And Sharper Net Loss - What's Changed

May 15, 2026 | finance.yahoo.com

Some Investors May Be Willing To Look Past SIGA Technologies' (NASDAQ:SIGA) Soft Earnings

May 14, 2026 | finance.yahoo.com

SIGA (SIGA) Q1 2026 Earnings Call Transcript

May 8, 2026 | fool.com

SIGA expects Q2 delivery of approximately $13M of oral TPOXX while targeting an FDA PEP submission in the next 12 months

May 8, 2026 | msn.com

SIGA Technologies, Inc. Q1 2026 Earnings Call Summary

May 8, 2026 | finance.yahoo.com

SIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call Transcript

May 8, 2026 | seekingalpha.com

SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update

May 7, 2026 | globenewswire.com

SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results

April 30, 2026 | globenewswire.com

Why SIGA Technologies, Inc.’s (SIGA) Stock Is Up 7.36%

March 28, 2026 | aaii.comA

SIGA mpox therapy no longer recommended in EU

March 27, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX, SIGA, NERV, and DERM Company Descriptions

Journey Medical NASDAQ:DERM

$7.86 -0.04 (-0.51%)

As of 04:00 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Eloxx Pharmaceuticals NASDAQ:ELOX

$15.00 +0.81 (+5.71%)

As of 04:00 PM Eastern

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Minerva Neurosciences NASDAQ:NERV

$4.43 -0.26 (-5.54%)

As of 04:00 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Siga Technologies NASDAQ:SIGA

$3.29 +0.06 (+1.86%)

As of 04:00 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELOX, SIGA, NERV, and DERM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELOX, SIGA, NERV, and DERM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELOX, SIGA, NERV, and DERM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX, SIGA, NERV, and DERM Company Descriptions

Journey Medical NASDAQ:DERM

Eloxx Pharmaceuticals NASDAQ:ELOX

Minerva Neurosciences NASDAQ:NERV

Siga Technologies NASDAQ:SIGA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELOX, SIGA, NERV, and DERM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELOX, SIGA, NERV, and DERM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELOX, SIGA, NERV, and DERM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX, SIGA, NERV, and DERM Company Descriptions

Journey Medical NASDAQ:DERM

Eloxx Pharmaceuticals NASDAQ:ELOX

Minerva Neurosciences NASDAQ:NERV

Siga Technologies NASDAQ:SIGA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools